Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Dec 11, 2025 · Filed Dec 15, 2025
A board member of Amphstar Pharmaceuticals sold $45K of Amphstar Pharmaceuticals shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$44,620
Shares × reported transaction price
35 days after results of Nov 6, 2025, 77 days before results of Feb 26, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.3% | +1.3% | +1.9% |
| 30 days | +1.5% | +2.0% | −0.5% |
| 90 days | −24.2% | −1.4% | −22.8% |
| 180 days | −23.0% | +11.2% | −34.2% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Amphstar Pharmaceuticals's SENIOR EVP, PRODUCTION CENTER sold $256K of Amphstar Pharmaceuticals shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.